Abalos Therapeutics GmbH

https://www.abalos-tx.com

LinkedIn: https://www.linkedin.com/company/abalos-the

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology. *

	Start	2019-09-25 established
	Industry	oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
	Industry 2	Fast Evolution platform (Abablos Therapeutics)
	Person	Kostka, Marcus (Abalos Therapeutics 201909– Managing Director (CEO) before Boehringer Ingelheim Venture Fund)
	Person 2	Vollmer, Jörg (Abalos Therapeutics 201910– CSO before Rigontec + Nexigen)

	Region	Düsseldorf
	Country	Germany
	Street	1A Merowinger Platz
	City	40225 Düsseldorf
	Tel	+49-211-540104-0
		Address record changed: 2022-09-17

Basic data	Employees	n. a.

		* Document for »About Section«: Abalos Therapeutics GmbH. (10/15/19). "Press Release: Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer". Essen.

		Record changed: 2023-12-30

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Abalos Therapeutics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)